1. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
- Author
-
Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, and Rietjens M
- Subjects
- Adult, Aged, Body Mass Index, Breast Neoplasms chemistry, Breast Neoplasms etiology, Breast Neoplasms therapy, Chemotherapy, Adjuvant, Female, Follow-Up Studies, Humans, Incidence, Italy epidemiology, Ki-67 Antigen analysis, Lymphatic Metastasis, Middle Aged, Multivariate Analysis, Neoplasm Grading, Neoplasm Recurrence, Local epidemiology, Neoplasm Staging, Obesity metabolism, Proportional Hazards Models, Radiotherapy, Adjuvant, Receptor, ErbB-2 analysis, Receptors, Estrogen analysis, Receptors, Progesterone analysis, Retrospective Studies, Risk Factors, Time Factors, Biomarkers, Tumor analysis, Breast Neoplasms pathology, Breast Neoplasms surgery, Mammaplasty, Neoplasm Recurrence, Local etiology, Obesity complications
- Abstract
Background: A small but significant proportion of patients with breast cancer (BC) will develop loco-regional recurrence (LRR) after immediate breast reconstruction (IBR). The LRR also varies according to breast cancer subtypes and clinicopathological features., Methods: We studied 1742 consecutive BC patients with IBR between 1997 and 2006. According to St Gallen conference consensus 2011, its BC approximations were applied to classify BC into five subtypes: estrogen receptor (ER) and/or progesterone receptor (PgR) positive, HER2 negative, and low Ki67 (<14%) [luminal A]; ER and/or PgR positive, HER2 negative and high Ki67(≥ 14%) [luminal B/HER2 negative]; ER and/or PgR positive, any Ki67 and HER2 positive [luminal B/HER2 positive]; ER negative, PgR negative and HER2 positive [HER2 positive/nonluminal]; and ER negative, PgR negative and HER2 negative [triple negative]. Cumulative incidences of LRR were compared across different subgroups by means of the Gray test. Multivariable Cox regression models were applied., Results: Median follow up time was 74 months (range 3-165). The cumulative incidence of LRR was 5.5% (121 events). The 5-year cumulative incidence of LRR was 2.5% for luminal A; 5.0% for luminal B/HER2 negative; 9.8% for luminal B/HER2 positive; 3.8% for HER2 non luminal; and 10.9% for triple negative. On multivariable analysis, tumor size (pT) >2 cm, body mass index (BMI) ≥ 25, triple negative and luminal B/HER2 positive subtypes were associated with increased risk of LRR., Conclusion: Luminal B/HER2 positive, triple negative subtypes and BMI ≥ 25 are independent prognostic factors for risk of LRR after IBR., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF